Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Study of IBI301 vs Rituximab in CD20+ B-cell Lymphoma
NCT02945215Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Dec 2016
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI301 in B cell lymphoma (2 arms), sponsored by Innovent Biologics. Primary endpoint: Area Under the Curve from time zero to infinity at 91 days. Started Dec 2016; status: completed.
02
Drugs
IBI301
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT02945215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02945215.